PriMera Scientific Surgical
Research and Practice
Volume 8 Issue 1 July 2026
DOI: 10.56831/PSSRP-08-290
ISSN: 2836-0028

PriMera Scientific Publications

Fluoroquinolone Toxicity (“Floxed”) and the Potential Role of Natural Ingredients in Recovery

Type: Review Article
Received: June 22, 2026
Published: July 21, 2026

Citation:
Christina Rahm. “Fluoroquinolone Toxicity (“Floxed”) and the Potential Role of Natural Ingredients in Recovery". PriMera Scientific Surgical Research and Practice 8.1 (2026): 251-263.

Christina Rahm*

DRC VENTURES LLC, USA

***Corresponding Author:** Christina Rahm, DRC VENTURES LLC, USA.

Fluoroquinolone antibiotics (FQs) are a class of broad-spectrum antimicrobial agents widely prescribed for respiratory, urinary tract, gastrointestinal, dermatologic, and systemic infections. Commonly utilized agents include ciprofloxacin, levofloxacin, and moxifloxacin. Due to their high bioavailability, excellent tissue penetration, and potent bactericidal activity, fluoroquinolones have become a mainstay in modern infectious disease management. However, while clinically effective, a growing body of scientific literature and post-marketing surveillance data has raised significant concerns regarding their safety profile. In certain individuals, fluoroquinolones have been associated with multisystem, persistent, and sometimes disabling adverse effects that extend well beyond the period of active treatment. These reactions may involve the neurological, musculoskeletal, mitochondrial, connective tissue, and autonomic nervous systems. Regulatory agencies, including the U.S. Food and Drug Administration (FDA), have issued multiple safety communications acknowledging risks such as tendon rupture, peripheral neuropathy, central nervous system effects, dysglycemia, and aortic complications. A subset of patients experiencing prolonged or severe adverse reactions frequently describe themselves as being “floxed,” a term coined within patient communities to describe fluoroquinolone-associated toxicity (FQT). Symptoms may emerge during treatment or develop weeks to months after discontinuation, and in some cases persist for years. Reported manifestations include chronic fatigue, tendon pain or rupture, neuropathy, cognitive impairment, dysautonomia, insomnia, anxiety, muscle weakness, and gastrointestinal disturbances. Increasing evidence suggests that these clinical presentations may be linked to mitochondrial dysfunction, oxidative stress, metal chelation, collagen degradation, altered gene expression, and immune dysregulation.

Given the complexity and multisystem nature of fluoroquinolone toxicity, recovery often requires a comprehensive and systems-based approach. This white paper examines the current scientific understanding of the molecular and physiological mechanisms underlying FQT, with particular emphasis on mitochondrial injury, oxidative imbalance, connective tissue disruption, and neuroinflammation. Furthermore, it explores evidence-based nutritional and botanical interventions that may support recovery by enhancing mitochondrial repair, restoring antioxidant capacity, replenishing essential minerals, stabilizing the nervous system, modulating immune responses, and promoting gastrointestinal and connective tissue healing. By integrating mechanistic insight with targeted, science-informed therapeutic strategies, this paper aims to provide clinicians, researchers, and affected individuals with a structured framework for understanding and addressing fluoroquinolone-associated toxicity.

What Does "Floxed" Mean?

The term "floxed" has emerged from patient communities to describe individuals who experience persistent, disabling, and often multisystem complications following exposure to fluoroquinolone antibiotics. Unlike the typical short-term adverse reactions associated with many medications, fluoroquinolone toxicity can present as a chronic and complex syndrome that extends far beyond the period of active treatment. Reported manifestations include tendon degeneration and rupture, peripheral neuropathy, cognitive impairment ("brain fog"), dysautonomia, psychiatric disturbances, mitochondrial dysfunction, and widespread connective tissue injury (Hussen et al., 2024). In more severe cases, patients describe profound fatigue, muscle wasting, joint instability, insomnia, sensory hypersensitivity, and long-term functional decline. A defining feature of fluoroquinolone-associated disability is its delayed and unpredictable onset. Symptoms may arise during treatment, shortly after discontinuation, or even weeks to months later, complicating clinical recognition. Because the presentation can mimic autoimmune disease, fibromyalgia, chronic fatigue syndrome, anxiety disorders, or idiopathic neuropathy, many affected individuals report that their concerns were initially dismissed or attributed to unrelated causes. This diagnostic delay frequently prolongs suffering and may exacerbate both physical deterioration and psychological distress. The lack of early recognition also limits timely intervention aimed at mitigating mitochondrial injury, oxidative stress, and connective tissue breakdown.

The collective identity of individuals who identify as "floxed" often referred to as "floxies" has developed through shared symptom patterns, online patient forums, and advocacy efforts aimed at increasing awareness within the medical community (Anwar et al., 2024). These communities have played a significant role in documenting symptom clusters, proposing mechanistic hypotheses, and advocating for stronger regulatory warnings and research funding. Their shared experience reflects not only the biological complexity of fluoroquinolone toxicity but also the broader challenges patients face when presenting with conditions that are poorly understood, under-recognized, or medically contested. As awareness grows, it is becoming increasingly clear that fluoroquinolone toxicity represents more than an isolated adverse drug reaction. Rather, it appears to be a systemic, biologically mediated condition involving mitochondrial dysfunction, oxidative damage, altered collagen integrity, immune dysregulation, and nervous system instability. Understanding the lived experience of "floxed" individuals is therefore essential not only for compassionate clinical care but also for advancing research into mechanisms, prevention strategies, and recovery protocols.

Why Are Fluoroquinolones Unique?

Fluoroquinolones possess unique pharmacological characteristics that distinguish them from many other classes of antibiotics. A defining structural feature is the addition of a fluorine atom to the quinolone backbone. This fluorination significantly enhances lipid solubility, membrane penetration, and overall tissue permeability (Du et al., 2023). As a result, fluoroquinolones demonstrate exceptional bioavailability and deep tissue distribution, allowing them to penetrate intracellular compartments and cross physiological barriers, including the blood-brain barrier. While this pharmacokinetic profile contributes to their clinical effectiveness against difficult-to-treat infections, it also underlies their potential for widespread tissue exposure. Fluoroquinolones accumulate in collagen-rich and metabolically active tissues, including tendons, ligaments, cartilage, fascia, peripheral nerves, vascular tissue (including the aorta), and central nervous system structures. Many of these tissues have high mitochondrial density and relatively limited regenerative capacity. Prolonged intracellular persistence in such tissues may amplify vulnerability to oxidative injury and structural degradation (Hong et al., 2024). At the molecular level, fluoroquinolones exert their antibacterial effect by inhibiting bacterial DNA gyrase and topoisomerase IV enzymes essential for DNA replication and transcription. However, emerging research suggests that these agents may also interfere with homologous topoisomerase enzymes within human mitochondria. Mitochondria retain their own circular DNA (mtDNA) and rely on tightly regulated replication and repair mechanisms. Disruption of mitochondrial topoisomerase function may impair mtDNA maintenance, reduce electron transport chain efficiency, and ultimately decrease ATP production (Fadda et al., 2025).

Beyond direct enzymatic interference, fluoroquinolones are recognized as potent inducers of oxidative stress. They have been shown to increase reactive oxygen species (ROS) production, deplete endogenous antioxidants such as glutathione, and alter redox signaling pathways. The resulting oxidative imbalance can damage mitochondrial membranes, proteins, and DNA, creating a self-perpetuating

cycle of mitochondrial dysfunction and cellular energy failure. Tissues with high energy demands such as skeletal muscle, cardiac muscle, peripheral nerves, and brain tissue may be particularly susceptible to this process. Additionally, fluoroquinolones possess metal-chelating properties, binding divalent and trivalent cations such as magnesium, iron, and zinc. Magnesium depletion, in particular, has been implicated in neuromuscular instability, arrhythmogenic potential, and impaired collagen synthesis. Given that collagen integrity depends on proper enzymatic cross-linking and mineral availability, chelation may contribute to tendon fragility, ligament laxity, and vascular wall weakening.

These mechanistic insights align with clinical observations that have prompted multiple black-box warnings from the U.S. Food and Drug Administration (FDA). Documented risks include tendonitis and tendon rupture (Baggio and Ananda-Rajah, 2021), irreversible peripheral neuropathy (Brant et al., 2024), disabling and potentially permanent multisystem toxicity (Lewis, 2022), increased risk of aortic aneurysm and dissection (Masadeh et al., 2020), and serious mental health and glycemic disturbances (Brant et al., 2024). The breadth of these warnings reflects the systemic impact of fluoroquinolones on connective tissue, the nervous system, metabolic regulation, and vascular integrity. Taken together, the combination of high tissue penetration, mitochondrial vulnerability, oxidative stress induction, and mineral chelation provides a plausible biological framework for understanding the multisystem nature of fluoroquinolone-associated toxicity. While these pharmacodynamic properties enhance antimicrobial potency, they also underscore the need for careful risk-benefit assessment and deeper investigation into protective and restorative strategies for affected individuals.

Mechanisms of Fluoroquinolone Toxicity

Mitochondrial Dysfunction

Mitochondrial dysfunction is increasingly recognized as a central mechanism underlying fluoroquinolone-associated toxicity. While fluoroquinolones are designed to inhibit bacterial DNA gyrase and topoisomerase IV, research suggests that they may also interfere with homologous topoisomerase enzymes within human mitochondria. Because mitochondria retain their own circular DNA (mtDNA), they rely on precise replication and repair processes to maintain normal cellular respiration. Inhibition of mitochondrial topoisomerase activity can impair mtDNA replication, disrupt transcription, and reduce the synthesis of essential proteins required for the electron transport chain (ETC). Damage to mtDNA compromises the integrity of ETC complexes I-V, resulting in impaired oxidative phosphorylation and reduced adenosine triphosphate (ATP) production. ATP is the primary energy currency of the cell, and tissues with high metabolic demands such as skeletal muscle, cardiac muscle, peripheral nerves, and the brain are particularly sensitive to ATP depletion. Clinically, reduced ATP availability manifests as profound fatigue, muscle weakness, exercise intolerance, slowed cognitive processing, poor stress resilience, and delayed recovery from physical exertion. Patients frequently report post-exertional symptom exacerbation, suggesting impaired mitochondrial reserve capacity.

Beyond reduced ATP synthesis, dysfunctional mitochondria become significant sources of reactive oxygen species (ROS). When electron flow through the ETC is disrupted, electrons may prematurely leak and react with molecular oxygen, forming superoxide and other ROS. Excessive ROS production overwhelms endogenous antioxidant systems, including glutathione, superoxide dismutase, and catalase. This oxidative imbalance damages mitochondrial membranes, proteins, and nucleic acids, creating a self-perpetuating cycle in which mitochondrial injury generates further oxidative stress, which in turn causes additional mitochondrial damage (Kang et al., 2023). Mitochondrial injury also affects calcium homeostasis and apoptotic signaling pathways. Dysregulated calcium handling can contribute to neuromuscular irritability, arrhythmias, and autonomic instability. Activation of intrinsic apoptotic pathways may lead to cell loss in vulnerable tissues, including neurons and myocytes. Over time, cumulative mitochondrial damage may impair tissue repair and regenerative capacity, contributing to the chronicity observed in some individuals with fluoroquinolone toxicity.

In addition, mitochondria play an essential role in immune signaling, steroid hormone synthesis, and redox regulation. Disruption of these functions may help explain the broad systemic manifestations seen in affected individuals, including dysautonomia, neuroinflammation, mood disturbances, and metabolic irregularities. The link between mitochondrial dysfunction and autonomic variability is particularly notable, as reduced ATP availability in autonomic ganglia and cardiac tissue may contribute to heart rate instability, orthostatic intolerance, and impaired stress adaptation. Taken together, mitochondrial dysfunction provides a biologically plausible

and unifying framework for understanding many of the neurological, musculoskeletal, metabolic, and autonomic symptoms reported after fluoroquinolone exposure. Recognizing mitochondrial injury as a core mechanism also underscores the importance of therapeutic strategies aimed at restoring mitochondrial biogenesis, reducing oxidative stress, replenishing essential cofactors, and supporting cellular energy metabolism.

Oxidative Stress

Oxidative stress represents a core pathological mechanism in fluoroquinolone-associated toxicity. Fluoroquinolones disrupt normal mitochondrial respiration by impairing components of the electron transport chain (ETC). When electron flow through the ETC becomes inefficient, electrons prematurely leak and react with molecular oxygen, forming superoxide anions and other reactive oxygen species (ROS). This overproduction of ROS overwhelms endogenous antioxidant defenses and shifts the cellular redox balance toward a pro-oxidant state. One of the most significant consequences of fluoroquinolone exposure is depletion of glutathione (GSH), the primary intracellular antioxidant and master regulator of redox homeostasis. Glutathione neutralizes ROS, supports detoxification pathways, and maintains mitochondrial membrane integrity. Reduced glutathione levels impair the cell's ability to buffer oxidative damage, leaving lipids, proteins, and nucleic acids vulnerable to attack. In addition, oxidative stress can further inhibit glutathione recycling enzymes, creating a vicious cycle of escalating redox imbalance. Excess ROS initiates lipid peroxidation within cellular and mitochondrial membranes, compromising membrane fluidity and permeability. This is particularly damaging in neurons and muscle cells, where membrane integrity is essential for signal transmission and contraction. ROS also oxidize structural and enzymatic proteins, altering their function and potentially triggering misfolding or degradation. DNA damage including both nuclear DNA and mitochondrial DNA further disrupts cellular repair mechanisms and energy production (Poulsen et al., 2021).

Connective tissue appears especially susceptible to oxidative injury. Collagen synthesis and cross-linking require tightly regulated enzymatic processes that depend on adequate redox balance. Oxidative stress may impair fibroblast function and weaken collagen integrity, contributing to tendon pain, ligament laxity, and delayed tissue repair. In nerve tissue, ROS-induced mitochondrial dysfunction and membrane damage can promote axonal degeneration and demyelination, mechanisms consistent with reports of peripheral neuropathy. Importantly, oxidative stress also activates inflammatory signaling pathways, including NF-κB and pro-inflammatory cytokine cascades. Persistent redox imbalance may therefore drive chronic, low-grade inflammation. This inflammatory-oxidative feedback loop may explain the episodic symptom flares reported by many individuals who identify as "floxed." Heightened oxidative sensitivity can make patients more reactive to physical stress, infections, psychological strain, or even minor metabolic disturbances.

Chronic oxidative damage has been strongly associated with persistent musculoskeletal pain, neuropathic symptoms, cognitive dysfunction, and systemic fatigue in individuals following fluoroquinolone exposure. The interplay between mitochondrial impairment and oxidative stress creates a self-sustaining cycle: damaged mitochondria produce more ROS, and increased ROS further damage mitochondria. Understanding oxidative stress as both a trigger and perpetuator of fluoroquinolone toxicity highlights the importance of therapeutic strategies aimed at restoring redox balance. Interventions that replenish glutathione, support endogenous antioxidant enzyme systems, stabilize mitochondrial membranes, and reduce inflammatory signaling may play a critical role in mitigating long-term tissue injury and supporting recovery.

Mineral Chelation

A distinctive biochemical property of fluoroquinolones is their strong affinity for divalent and trivalent cations. These agents readily chelate minerals such as magnesium (Mg^{2+}), calcium (Ca^{2+}), iron (Fe^{2+}/Fe^{3+}), and zinc (Zn^{2+}). While this chelating capability contributes to their antimicrobial action by interfering with bacterial enzyme stability it may also disrupt essential mineral-dependent processes in human tissues (Khaleel et al., 2022). Magnesium appears to be particularly significant in the context of fluoroquinolone toxicity. As a critical cofactor in more than 300 enzymatic reactions, magnesium is indispensable for ATP synthesis, mitochondrial stability, DNA repair, ion channel regulation, and neuromuscular signaling. In fact, ATP biologically exists as a magnesium-ATP complex; without sufficient magnesium, cellular energy production becomes inefficient. When fluoroquinolones bind and reduce bioavailable

magnesium, mitochondrial ATP generation may decline further, compounding existing mitochondrial dysfunction.

Magnesium also plays a central role in stabilizing excitable membranes. It regulates calcium influx through voltage-gated channels and modulates NMDA (N-methyl-D-aspartate) receptors in the nervous system. Reduced magnesium availability may therefore lead to excessive neuronal firing and heightened neuromuscular excitability. Clinically, this can manifest as muscle cramps, fasciculations, tremors, heightened startle response, anxiety, insomnia, palpitations, and autonomic instability. In connective tissue, magnesium contributes to collagen synthesis and structural integrity. Collagen cross-linking and extracellular matrix maintenance depend on mineral-supported enzymatic pathways. Chelation-induced magnesium depletion may weaken tendons and ligaments, increasing susceptibility to tendinopathy and rupture. This mechanism aligns with the well-documented association between fluoroquinolones and tendon injury, particularly involving the Achilles tendon. Calcium balance may also be disrupted. Magnesium and calcium exist in tightly regulated physiological equilibrium. When magnesium levels fall, calcium influx into cells may become excessive, promoting muscle tightness, vascular constriction, and increased oxidative stress. Elevated intracellular calcium can further impair mitochondrial function and activate inflammatory pathways. Iron and zinc chelation may additionally influence oxidative balance and immune regulation. Iron is critical for mitochondrial electron transport chain complexes, while zinc is necessary for antioxidant enzymes such as superoxide dismutase (SOD). Disturbances in these minerals may amplify oxidative stress and delay tissue repair.

The combined effects of mineral chelation can therefore contribute to a constellation of symptoms, including neuromuscular hyperexcitability, persistent muscle pain, tremors, arrhythmogenic sensations, mood disturbances, and increased vulnerability to connective tissue injury. In individuals already predisposed to low magnesium status due to stress, poor dietary intake, gastrointestinal dysfunction, or concurrent medications the impact may be amplified. Understanding mineral chelation as a contributory mechanism in fluoroquinolone toxicity highlights the importance of evaluating and restoring mineral balance as part of a comprehensive recovery strategy. Addressing magnesium sufficiency, stabilizing calcium homeostasis, and supporting trace mineral replenishment may help mitigate neuromuscular instability, protect connective tissue integrity, and support mitochondrial energy production.

Collagen and Tendon Toxicity

Collagen and connective tissue toxicity represent one of the most well-documented and clinically recognized adverse effects associated with fluoroquinolone exposure. Fluoroquinolones have been shown to disrupt collagen homeostasis through multiple mechanisms, including inhibition of collagen synthesis, impairment of fibroblast function, induction of matrix metalloproteinases (MMPs), and interference with collagen cross-linking enzymes (Mani et al., 2025). Collagen is the primary structural protein in tendons, ligaments, fascia, cartilage, skin, and vascular connective tissue. Its integrity depends on tightly regulated synthesis, proper enzymatic cross-linking (involving lysyl oxidase and other cofactors), and balanced extracellular matrix remodeling. Fluoroquinolones appear to upregulate MMP activity enzymes responsible for collagen degradation while simultaneously impairing new collagen production. This imbalance shifts connective tissue toward catabolism, weakening tensile strength and structural stability.

Oxidative stress further compounds this process. Elevated reactive oxygen species (ROS) can damage collagen fibers directly and impair fibroblast proliferation. Additionally, mineral chelation particularly of magnesium and possibly copper may interfere with enzymatic processes required for collagen maturation and cross-link stabilization. The combined effect is reduced structural integrity and increased susceptibility to microtears and degeneration. Tendon tissue is particularly vulnerable due to its limited vascular supply and low baseline cellular turnover. Unlike muscle tissue, tendons receive relatively poor blood flow, meaning that nutrient delivery and waste removal are inherently slower. When injury occurs whether through mechanical stress or biochemical disruption healing is prolonged. In the context of fluoroquinolone exposure, ongoing oxidative stress and impaired collagen remodeling may further delay recovery and increase the risk of incomplete repair.

Clinically, this manifests as tendonitis, tendon pain, stiffness, and in severe cases, spontaneous tendon rupture. The Achilles tendon is most commonly affected, likely due to its high mechanical load and relatively poor vascularization, but other tendons including those of the shoulder, hand, and quadriceps may also be involved. Some patients report diffuse fascial pain and joint instability, suggesting

broader extracellular matrix involvement beyond isolated tendon injury. Vascular connective tissue may also be impacted. The aorta and other large vessels rely heavily on collagen and elastin for structural integrity. Disruption of collagen stability in vascular tissue has been proposed as a contributing factor to the increased risk of aortic aneurysm and dissection observed in some fluoroquinolone-exposed populations.

Importantly, connective tissue injury may not present immediately. Symptoms can develop during treatment or weeks to months afterward, reflecting cumulative collagen degradation and delayed structural failure. Because tendon healing is inherently slow and because collagen turnover can take months recovery may be prolonged, and in some cases incomplete. Understanding collagen and tendon toxicity as a multifactorial process involving oxidative stress, enzymatic dysregulation, mitochondrial impairment, and mineral imbalance provides a more comprehensive framework for both prevention and recovery. Therapeutic strategies that support collagen synthesis, regulate MMP activity, restore mineral sufficiency, and reduce oxidative damage may be essential components of connective tissue rehabilitation in individuals affected by fluoroquinolone-associated toxicity.

Neurotoxicity and GABA Disruption

Neurotoxicity is one of the most distressing and functionally limiting aspects of fluoroquinolone-associated toxicity. A key mechanism underlying central nervous system (CNS) symptoms involves disruption of gamma-aminobutyric acid (GABA) signaling. Fluoroquinolones are known to act as GABA-A receptor antagonists, meaning they interfere with the primary inhibitory neurotransmitter system in the brain. GABA-A receptors regulate neuronal excitability by allowing chloride ions to enter neurons, stabilizing membrane potential and preventing excessive firing. When fluoroquinolones block or reduce GABA-A receptor activity, inhibitory tone diminishes and neuronal excitability increases. This loss of inhibitory regulation can lead to a hyperexcitable CNS state. Clinically, patients may experience anxiety, agitation, panic attacks, insomnia, inner restlessness, tremors, and heightened sensory sensitivity. In more severe cases, seizures or acute psychosis have been reported. The intensity of these symptoms may be amplified in individuals concurrently using nonsteroidal anti-inflammatory drugs (NSAIDs) or other medications that further influence GABAergic signaling.

In addition to GABA antagonism, fluoroquinolones may alter glutamatergic activity, further tipping the balance toward excitatory neurotransmission. The combined effect of reduced inhibition and heightened excitation creates a state of neurochemical instability, often described by affected individuals as feeling "wired but exhausted." This phenomenon may contribute to persistent insomnia and autonomic dysregulation. Mitochondrial dysfunction compounds these neurochemical effects. Neurons are highly energy-dependent cells, requiring substantial ATP to maintain ion gradients, neurotransmitter recycling, and synaptic transmission. Impaired mitochondrial ATP production disrupts sodium-potassium pump function and calcium homeostasis, leading to altered electrical signaling. Mitochondrial injury within neurons and glial cells also increases oxidative stress, which can damage myelin sheaths and axonal membranes.

Peripheral neuropathy associated with fluoroquinolones is believed to arise from a combination of mitochondrial injury, oxidative stress, and altered ion channel function. Damage to peripheral nerve mitochondria reduces energy availability for axonal transport and repair. Excess ROS can injure Schwann cells and contribute to demyelination. Clinically, this manifests as burning pain, numbness, tingling, hypersensitivity, altered temperature perception, or electric-shock sensations. In some cases, symptoms persist long after discontinuation, suggesting structural or long-term functional nerve changes. Neuroinflammation may also play a role. Oxidative stress activates microglia and inflammatory signaling pathways within the CNS, potentially perpetuating neuronal dysfunction. This inflammatory component may contribute to cognitive symptoms such as impaired concentration, slowed processing speed, memory disturbances, and mood instability.

The interplay between GABA disruption, mitochondrial dysfunction, oxidative stress, and inflammatory signaling creates a multifactorial model of fluoroquinolone-induced neurotoxicity. Rather than a singular neurotransmitter effect, the condition appears to involve widespread dysregulation of neuronal energy metabolism and inhibitory-excitatory balance. Recognizing these mechanisms is critical for understanding why neuropsychiatric and neuropathic symptoms may be both severe and persistent. It also underscores

the importance of therapeutic strategies aimed at restoring redox balance, supporting mitochondrial repair, stabilizing inhibitory neurotransmission, and protecting peripheral nerve integrity in affected individuals.

Gut Dysbiosis and Immune Activation

Fluoroquinolones exert potent antimicrobial effects that extend beyond pathogenic organisms and significantly alter the composition and diversity of the gut microbiome. As broad-spectrum agents, they reduce commensal bacterial populations particularly beneficial genera involved in short-chain fatty acid (SCFA) production, mucosal integrity, and immune regulation. This disruption can lead to microbial imbalance, or dysbiosis, characterized by decreased microbial diversity, overgrowth of opportunistic species, and impaired metabolic signaling within the gut ecosystem (Huang et al., 2022). The gut microbiome plays a central role in maintaining intestinal barrier integrity. Beneficial bacteria produce SCFAs such as butyrate, which nourish colonocytes, reinforce tight junction proteins (e.g., occludin and claudins), and regulate local immune responses. When these protective microbial populations are depleted, tight junction stability may be compromised, increasing intestinal permeability often referred to as "leaky gut."

Heightened intestinal permeability allows lipopolysaccharides (LPS) and other endotoxins derived from gram-negative bacteria to translocate into systemic circulation. Circulating endotoxins activate toll-like receptors (TLRs) and trigger downstream inflammatory signaling pathways, including NF-κB activation and cytokine release. This systemic immune activation can contribute to chronic low-grade inflammation and may amplify pre-existing oxidative stress and mitochondrial dysfunction. Persistent immune stimulation may also alter mast cell stability. Mast cells, which play a critical role in immune surveillance and inflammatory signaling, can become hyperresponsive in the setting of ongoing endotoxin exposure and oxidative stress. Mast cell activation may lead to excessive histamine release and the development of symptoms such as flushing, pruritus, gastrointestinal distress, tachycardia, anxiety, and food reactivity. This mechanism may help explain why some individuals report new-onset food sensitivities, histamine intolerance, and systemic hypersensitivity following fluoroquinolone exposure. In susceptible individuals, chronic immune activation and altered microbiome signaling may mimic or exacerbate autoimmune-like phenomena. Molecular mimicry, dysregulated T-cell responses, and persistent inflammatory signaling can blur the distinction between infection-related immune activation and autoimmunity. While not all patients develop true autoimmune disease, the inflammatory environment may produce overlapping symptoms such as joint pain, fatigue, cognitive changes, and heightened immune reactivity.

Furthermore, the gut-brain axis is intimately connected to microbiome health. Dysbiosis can influence neurotransmitter production, vagal signaling, and neuroinflammatory pathways. Reduced production of microbial metabolites involved in serotonin and GABA modulation may compound central nervous system symptoms such as anxiety, mood instability, and sleep disturbances. Thus, gut disruption may not only affect gastrointestinal health but also contribute to neuropsychiatric manifestations. Taken together, gut dysbiosis represents more than a localized gastrointestinal disturbance it may serve as a systemic amplifier of inflammation, oxidative stress, immune dysregulation, and neurologic instability. Recognizing the role of microbiome disruption in fluoroquinolone-associated toxicity highlights the importance of strategies aimed at restoring microbial diversity, strengthening intestinal barrier function, modulating mast cell activity, and recalibrating immune balance as part of a comprehensive recovery approach.

Natural Ingredients and Nutritional Support in Recovery

Because fluoroquinolone toxicity is multisystemic affecting mitochondria, connective tissue, the nervous system, immune regulation, mineral balance, and the gut microbiome recovery must likewise be systemic and integrative. There is currently no single pharmaceutical "antidote" for fluoroquinolone-associated toxicity (FQT). Discontinuation of the drug is the first and most essential step; however, for individuals who develop persistent symptoms, additional therapeutic strategies are often required to support physiologic repair and functional restoration. A systems-based recovery model focuses on correcting the underlying biological disruptions identified in FQT, including mitochondrial dysfunction, oxidative stress, mineral depletion, collagen degradation, neurochemical imbalance, and microbiome dysbiosis. Targeted nutritional and botanical interventions may play a supportive role in restoring homeostasis and improving resilience across these domains.

Given the central role of mitochondrial injury in FQT, interventions that promote mitochondrial biogenesis, stabilize the electron transport chain, and enhance ATP production are foundational. Nutrients such as Coenzyme Q10 (CoQ10), acetyl-L-carnitine, alpha-lipoic acid, riboflavin, magnesium, and B-complex vitamins support oxidative phosphorylation and mitochondrial membrane integrity. Certain polyphenols, including resveratrol and quercetin, have been studied for their ability to modulate mitochondrial signaling pathways and reduce oxidative burden. Replenishing endogenous antioxidant systems is critical to interrupt the cycle of oxidative damage. Glutathione repletion either directly or through precursor support (e.g., N-acetylcysteine, glycine) may enhance detoxification and cellular defense mechanisms. Vitamin C, vitamin E, selenium, and plant-derived antioxidants can help neutralize reactive oxygen species and reduce lipid peroxidation. Supporting the body's intrinsic antioxidant enzymes (such as superoxide dismutase and catalase) is equally important for long-term redox stability.

Because fluoroquinolones chelate essential minerals, careful repletion of magnesium and trace elements may improve neuromuscular stability, mitochondrial ATP synthesis, and connective tissue resilience. Magnesium, in particular, plays a critical role in regulating NMDA receptors, stabilizing cardiac rhythm, and supporting collagen integrity. Restoration of mineral balance may reduce symptoms such as muscle cramps, tremors, palpitations, and autonomic variability. Supporting collagen synthesis and extracellular matrix repair is essential in individuals with tendon and ligament involvement. Nutrients such as vitamin C (a cofactor for collagen hydroxylation), glycine, proline, lysine, copper, and silica contribute to structural protein formation. Botanical compounds with anti-inflammatory and matrix-stabilizing properties may help modulate excessive MMP activity and promote balanced tissue remodeling. Because fluoroquinolones disrupt inhibitory neurotransmission and promote neuronal excitability, calming and neuroprotective nutrients may be beneficial. Magnesium, L-theanine, taurine, omega-3 fatty acids, and certain adaptogenic botanicals may help stabilize excitatory-inhibitory balance. Supporting mitochondrial function within neurons further enhances synaptic stability and cognitive recovery.

Gut Microbiome and Immune Modulation

Restoring microbial diversity and strengthening the intestinal barrier are critical for reducing systemic inflammation. Prebiotic fibers, targeted probiotics, butyrate-supporting interventions, and gut-healing nutrients (such as zinc, glutamine, and polyphenols) may improve mucosal integrity and recalibrate immune signaling. Modulating mast cell activity and histamine balance may reduce hypersensitivity reactions and food reactivity. Importantly, recovery is often gradual. Tissue remodeling, mitochondrial repair, and nervous system recalibration occur over weeks to months rather than days. A phased and individualized protocol tailored to symptom severity, tolerance, and comorbid conditions is typically most effective. Overaggressive supplementation in highly sensitive individuals may exacerbate symptoms; therefore, gradual introduction and careful monitoring are recommended. While more clinical research is needed to establish standardized treatment guidelines, current mechanistic understanding supports the role of targeted nutritional strategies in mitigating oxidative damage, restoring metabolic balance, and promoting structural repair. An integrative recovery framework does not replace conventional medical evaluation but may serve as a complementary approach aimed at supporting the body's inherent capacity for repair and adaptation.

Mitochondrial and Antioxidant Support

Targeted mitochondrial and antioxidant support represents a cornerstone of recovery strategies in fluoroquinolone-associated toxicity, given the central role of oxidative stress and impaired energy metabolism in symptom development. Polyphenolic compounds such as resveratrol, curcumin, quercetin, pine bark extract (rich in proanthocyanidins), and astaxanthin have demonstrated antioxidant, anti-inflammatory, and mitochondrial-stabilizing properties in preclinical and emerging clinical research. These compounds help neutralize reactive oxygen species (ROS), reduce lipid peroxidation, and protect mitochondrial membranes from oxidative injury (Kang et al., 2023). By preserving mitochondrial membrane integrity, they support proper electron transport chain function and reduce electron leakage that would otherwise perpetuate oxidative stress. Beyond direct antioxidant activity, many of these compounds modulate intracellular signaling pathways involved in mitochondrial biogenesis and cellular resilience. For example, resveratrol has been shown to activate sirtuin pathways (notably SIRT1), which influence mitochondrial replication and metabolic efficiency. Curcumin and quercetin have been observed to regulate inflammatory cascades such as NF-κB, thereby reducing cytokine-driven oxidative

amplification. Pine bark extract contributes vascular and microcirculatory support, potentially enhancing oxygen and nutrient delivery to metabolically compromised tissues. Astaxanthin, a lipid-soluble carotenoid, integrates into mitochondrial membranes, where it may provide targeted protection against oxidative damage in high-energy tissues such as skeletal muscle and neurons.

In addition to redox modulation, restoring cellular energy substrates is critical. D-ribose plays a direct role in the synthesis of adenine nucleotides and may help replenish depleted ATP pools by supporting the pentose phosphate pathway and nucleotide salvage pathways. NAD^+ precursors, such as nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN), support mitochondrial respiration by replenishing intracellular NAD^+ levels, a coenzyme essential for oxidative phosphorylation and cellular repair processes. Adequate NAD^+ availability also supports sirtuin activity and DNA repair enzymes, potentially aiding recovery from mitochondrial DNA injury. Together, these mitochondrial-supportive nutrients address both upstream and downstream consequences of fluoroquinolone-induced oxidative stress. By reducing ROS burden, stabilizing mitochondrial membranes, supporting ATP regeneration, and modulating inflammatory signaling, they may help interrupt the cycle of mitochondrial dysfunction and energy failure. Although further clinical trials are needed to establish standardized dosing protocols in fluoroquinolone toxicity specifically, mechanistic evidence supports their potential role as part of a comprehensive, systems-based recovery strategy aimed at restoring metabolic resilience and cellular homeostasis.

Mineral Repletion

Because fluoroquinolones possess strong chelating properties, mineral depletion particularly of magnesium represents a significant and often underrecognized component of fluoroquinolone-associated toxicity. Magnesium is an essential cofactor in hundreds of enzymatic reactions and is fundamental to ATP synthesis, mitochondrial stability, neuromuscular transmission, cardiac rhythm regulation, and connective tissue integrity. Since biologically active ATP exists as a magnesium-ATP complex, insufficient magnesium availability can further impair already compromised mitochondrial energy production. Repletion with highly bioavailable forms of magnesium such as magnesium glycinate, malate, threonate, or citrate may help restore neuromuscular stability, reduce muscle cramps and fasciculations, support autonomic balance, and improve stress resilience.

Magnesium also plays a regulatory role in calcium homeostasis and NMDA receptor modulation. Adequate intracellular magnesium helps prevent excessive calcium influx into cells, which can otherwise promote excitotoxicity, oxidative stress, and mitochondrial dysfunction. In the cardiovascular system, magnesium contributes to electrical stability of the myocardium and may reduce palpitations or arrhythmic sensations that some individuals experience following fluoroquinolone exposure. In skeletal muscle and peripheral nerves, magnesium supports proper membrane polarization and signal conduction, potentially reducing tremors, hypersensitivity, and neuromuscular irritability. Beyond magnesium, trace minerals contribute to structural and enzymatic repair processes. Silica (orthosilicic acid), for example, plays a role in collagen synthesis and extracellular matrix organization, supporting tendon, ligament, and vascular integrity. Adequate silica availability may enhance fibroblast function and collagen cross-linking, which are critical for connective tissue repair. Other trace elements such as zinc, copper, and selenium serve as cofactors for antioxidant enzymes and tissue remodeling pathways. Zinc supports immune regulation and wound healing, copper is required for lysyl oxidase-mediated collagen cross-linking, and selenium is integral to glutathione peroxidase activity, helping reduce oxidative burden.

Restoring mineral balance may also support detoxification pathways. Many detoxification enzymes depend on adequate trace mineral availability to function efficiently. Additionally, correcting deficiencies may improve cellular resilience and reduce sensitivity to environmental or metabolic stressors. Importantly, mineral repletion should be approached thoughtfully and individualized, as excessive or poorly balanced supplementation can disrupt mineral ratios or exacerbate symptoms in highly sensitive individuals. Overall, addressing mineral depletion is a foundational component of recovery. By replenishing magnesium and essential trace elements, it is possible to support mitochondrial energy production, stabilize neuromuscular and cardiac function, reinforce connective tissue integrity, and enhance antioxidant defense systems. This integrative mineral strategy complements mitochondrial and redox-focused interventions, contributing to a more comprehensive and physiologically grounded recovery framework (Khaleel et al., 2022).

Collagen and Connective Tissue Repair

Restoration of connective tissue integrity is a critical component of recovery in individuals experiencing fluoroquinolone-associated tendon and ligament injury. Because fluoroquinolones can disrupt collagen synthesis, increase matrix degradation, and impair fibroblast function, targeted nutritional substrates are essential to support structural rebuilding. Collagen peptides provide readily absorbable amino acid sequences particularly glycine, proline, and hydroxyproline that serve as foundational building blocks for new collagen formation. These peptides may stimulate fibroblast activity and enhance extracellular matrix remodeling, especially when paired with adequate vitamin C, which is required for the hydroxylation of proline and lysine during collagen synthesis. Without sufficient vitamin C, newly formed collagen fibers lack tensile strength and structural stability. Silica (especially in bioavailable orthosilicic acid form) further contributes to connective tissue health by supporting collagen cross-linking and glycosaminoglycan formation within the extracellular matrix. Silica has been associated with improved elasticity and structural resilience in tendons, ligaments, and vascular tissue.

Essential amino acids including lysine and methionine are also necessary for proper collagen assembly and repair, while adequate copper supports lysyl oxidase activity, the enzyme responsible for stabilizing collagen cross-links. Beyond structural substrates, controlling inflammation is vital for effective tissue repair. Chronic low-grade inflammation can impair fibroblast function and perpetuate matrix degradation. Omega-3 fatty acids, particularly EPA and DHA, help modulate inflammatory pathways by influencing eicosanoid production and reducing pro-inflammatory cytokine signaling. These fatty acids also integrate into cell membranes, enhancing membrane fluidity and resilience, which is particularly relevant for neuronal membranes and peripheral nerve recovery. By supporting anti-inflammatory resolution pathways, omega-3s may help reduce tendon pain and improve tissue remodeling dynamics.

Astaxanthin provides targeted antioxidant protection within lipid-rich tissues, including cell membranes of connective and neural structures. As a potent carotenoid antioxidant, it embeds within phospholipid bilayers and helps reduce lipid peroxidation caused by oxidative stress. Protecting connective tissue cells from oxidative damage is especially important in the context of fluoroquinolone exposure, where mitochondrial dysfunction and redox imbalance can delay healing and weaken structural proteins (Reinhardt et al., 2025). Collectively, collagen peptides, vitamin C, silica, essential amino acids, omega-3 fatty acids, and astaxanthin address both the structural and inflammatory components of connective tissue repair. This integrative approach supports collagen synthesis, stabilizes extracellular matrix architecture, modulates inflammation, and protects regenerating tissues from oxidative injury. Because tendons and ligaments are relatively avascular and heal slowly, consistent and sustained nutritional support may be necessary over an extended period to promote meaningful recovery and restore mechanical strength.

Nervous System and Neurotransmitter Balance

Restoring balance within the nervous system is a critical component of recovery, particularly in individuals experiencing central hyperexcitability, anxiety, insomnia, and autonomic instability following fluoroquinolone exposure. Because fluoroquinolones may disrupt GABAergic signaling and alter excitatory-inhibitory balance in the brain, supportive strategies should aim to calm neuronal overactivation while also stabilizing neurotransmitter production and stress-response pathways. L-theanine, an amino acid naturally found in green tea, has been shown to promote alpha brain wave activity and support a relaxed yet alert mental state. Mechanistically, L-theanine may modulate glutamate receptors and enhance GABA production, thereby helping to rebalance excitatory neurotransmission. By supporting inhibitory tone without causing sedation, it may reduce anxiety, restlessness, and sensory hypersensitivity while improving sleep quality. Its ability to buffer stress responses makes it particularly relevant in individuals experiencing heightened sympathetic nervous system activity.

N-acetyl-L-tyrosine (NALT), a bioavailable precursor to dopamine and norepinephrine, supports catecholamine synthesis, which may be compromised in the setting of mitochondrial dysfunction and chronic stress. Dopamine plays a key role in motivation, focus, and motor control, while norepinephrine influences alertness and autonomic regulation. Carefully titrated support of catecholamine pathways may help improve cognitive clarity, mood stability, and stress resilience, particularly in individuals experiencing "brain fog"

or dysregulated autonomic responses. Botanical adaptogens such as Rhodiola rosea, Ashwagandha (Withania somnifera), and Holy Basil (Ocimum sanctum) may further support nervous system equilibrium by modulating the hypothalamic-pituitary-adrenal (HPA) axis. Adaptogens help the body respond more efficiently to physiological stress, reducing cortisol fluctuations and sympathetic overdrive. Ashwagandha, in particular, has demonstrated potential to enhance GABA receptor activity and reduce anxiety, while Rhodiola may support mitochondrial efficiency and mental stamina.

In the context of GABA disruption and excitotoxic stress, magnesium also plays a complementary role by regulating NMDA receptor activity and stabilizing neuronal membranes. When integrated with calming amino acids and adaptogenic botanicals, this approach may help reduce panic symptoms, insomnia, palpitations, and autonomic variability. Overall, nervous system support in fluoroquinolone-associated toxicity should focus on restoring inhibitory-excitatory balance, improving mitochondrial energy availability in neurons, and stabilizing stress-response pathways. Through targeted nutritional and botanical strategies, it may be possible to reduce central hyperexcitability, enhance sleep quality, support neurotransmitter production, and promote a more regulated and resilient autonomic state.

Gut and Immune Support

Restoration of gut integrity and immune balance is a foundational component of recovery in individuals experiencing chronic symptoms following fluoroquinolone exposure. Because fluoroquinolones significantly disrupt the gut microbiome, reducing beneficial commensal bacteria and impairing short-chain fatty acid (SCFA) production, targeted nutritional strategies are essential to rebuild microbial diversity and strengthen the intestinal barrier. Prebiotic fibers such as inulin serve as fermentable substrates for beneficial bacteria, promoting the growth of Bifidobacteria and other SCFA-producing organisms. Increased butyrate production, in particular, supports colonocyte health, enhances tight junction protein expression, and reinforces mucosal integrity.

Plant-based polyphenols further contribute to microbiome restoration by acting as both antioxidants and selective microbial modulators. Compounds derived from berries, green tea, and other botanicals can reduce oxidative stress within the gut environment while promoting the proliferation of beneficial microbial strains. Polyphenols also influence inflammatory signaling pathways, helping to downregulate NF-κB activity and reduce pro-inflammatory cytokine release, which may otherwise perpetuate systemic immune activation. Aloe vera provides additional mucosal support through its soothing and anti-inflammatory properties. Its polysaccharides may help calm gastrointestinal irritation, support epithelial repair, and modulate immune responses at the gut barrier. Colostrum, rich in immunoglobulins, lactoferrin, growth factors, and bioactive peptides, can further strengthen intestinal permeability defenses. By supporting epithelial regeneration and binding endotoxins, colostrum may help reduce translocation of lipopolysaccharides (LPS) into systemic circulation. Stabilizing the gut barrier reduces the burden of circulating endotoxins that activate toll-like receptors and trigger systemic inflammatory cascades. Decreasing intestinal permeability may therefore help lower chronic immune activation, mast cell reactivity, and cytokine-driven symptom flares. Since persistent inflammation and immune dysregulation are central contributors to fatigue, neuropathy, connective tissue pain, and hypersensitivity reactions in individuals who identify as "floxed," addressing gut dysfunction can have far-reaching systemic effects (Romanowska et al., 2025).

Moreover, the gut-brain axis plays a critical role in neurotransmitter production and autonomic regulation. A balanced microbiome supports the synthesis of serotonin precursors and influences GABA signaling, potentially improving mood stability, sleep quality, and stress resilience. By repairing the gut barrier and restoring microbial equilibrium, it is possible not only to reduce systemic inflammation but also to promote more stable neuroimmune communication. Overall, gut and immune support should be viewed as a central pillar of recovery. Through the combined actions of prebiotic fibers, polyphenols, aloe vera, and colostrum, this approach addresses barrier integrity, microbial diversity, immune modulation, and inflammatory regulation helping to recalibrate systemic physiology and reduce the chronic symptom burden associated with fluoroquinolone toxicity.

Conclusion

Fluoroquinolone toxicity represents an under-recognized yet potentially severe multisystem adverse drug reaction that can persist long after the medication has been discontinued. While fluoroquinolones are highly effective antimicrobial agents, their unique chemical structure particularly the addition of a fluorine atom enhances lipid solubility and tissue penetration. This allows deep intracellular access and broad distribution across connective tissue, the central and peripheral nervous systems, vascular structures, and the gastrointestinal tract. However, these same pharmacokinetic advantages may predispose susceptible individuals to widespread biological disruption. Emerging evidence links fluoroquinolone exposure to mitochondrial dysfunction, oxidative stress amplification, mineral chelation, connective tissue degradation, neurotoxicity, gut microbiome imbalance, and secondary immune activation. Together, these mechanisms form a complex and interrelated pathophysiological network that helps explain the chronic, multisystem symptom patterns reported by affected individuals.

Conventional medical management of fluoroquinolone toxicity has largely focused on symptom control addressing pain, neuropathy, insomnia, or mood disturbances individually rather than targeting the underlying cellular injury. At present, no universally accepted pharmacologic "reversal" therapy exists. However, growing mechanistic insight into mitochondrial injury, redox imbalance, collagen disruption, and immune dysregulation has opened the door to integrative recovery models grounded in cellular physiology. Increasing research suggests that targeted nutritional and naturally derived compounds may support restoration by addressing root biological disturbances rather than isolated symptoms alone. A rational recovery framework therefore emphasizes mitochondrial repair and energy restoration, antioxidant replenishment to rebalance redox homeostasis, strategic mineral repletion to correct chelation-related deficiencies, and connective tissue support to rebuild structural integrity. In parallel, nervous system stabilization strategies aim to restore inhibitory-excitatory balance and reduce central hyperexcitability, while gut-directed therapies work to repair intestinal barrier function and recalibrate immune signaling. Because these systems are deeply interconnected mitochondrial health influences immune regulation, gut integrity affects neuroinflammation, and mineral balance impacts collagen stability an interdisciplinary, systems-based approach offers a more comprehensive path toward functional recovery.

While clinical research specific to fluoroquinolone toxicity remains limited, the convergence of mechanistic data and patient-reported outcomes underscores the importance of further scientific investigation. Greater clinical recognition, standardized diagnostic criteria, and controlled therapeutic trials are urgently needed to clarify optimal intervention strategies and improve outcomes. By integrating cellular biology with personalized, supportive care strategies, it may be possible to provide meaningful relief and long-term restoration for individuals affected by this complex and often debilitating condition.

References

1. Anwar AI., et al. "Fluoroquinolones: neurological complications and side effects in clinical practice". Cureus 16.2 (2024).
2. Baggio D and Ananda-Rajah MR. "Fluoroquinolone antibiotics and adverse events". Australian prescriber 44.5 (2021): 161-164.
3. Brant A., et al. "Antibiotic Use in Hospital Urinary Tract Infections After FDA Regulation". Journal of general internal medicine 39.8 (2024): 1414-1422.
4. Du J., et al. "The research status, potential hazards and toxicological mechanisms of fluoroquinolone antibiotics in the environment". Antibiotics 12.6 (2023): 1058.
5. Fadda H., et al. "Antibacterials exert toxic effects on aquatic organisms by inhibiting respiration, inducing oxidative stress, mitochondrial dysfunction and autophagy". Aquatic Toxicology 280 (2025): 107284.
6. Hong Y., et al. "Short-term exposure to antibiotics begets long-term disturbance in gut microbial metabolism and molecular ecological networks". Microbiome 12.1 (2024): 80.
7. Huang C., et al. "Effects of four antibiotics on the diversity of the intestinal microbiota". Microbiology spectrum 10.2 (2022): e01904-21.
8. Hussen NHA., et al. "Long-term toxicity of fluoroquinolones: a comprehensive review". Drug and chemical toxicology 47.5 (2024): 795-806.

9. Jiang T., et al. "Mitochondrial dysfunction is underlying fluoroquinolone toxicity: an integrated mitochondrial toxicity assessment". Molecular & Cellular Toxicology 19.2 (2023): 333-342.
10. Khaleel AK., et al. "Toxicological Aspects of Fluoroquinolones Administration: A Literature Review". Egyptian Journal of Chemistry 65.5 (2022): 561-569.
11. Lewis MP. "Fluoroquinolone Toxicity: From Mysterious Internet Illness to My New Reality-A Memoir of My Bout with Levofloxacin". Stimulus: A Medical Humanities Journal 2 (2022): 47-47.
12. Mani S., et al. "Drug-induced oxidative stress and cellular toxicity. In Free Radical Biology and Environmental Toxicity". Cham: Springer International Publishing (2022): 73-113.
13. Masadeh MM., et al. "Vitamin D Pretreatment Attenuates Ciprofloxacin-Induced Antibacterial Activity". Clinical pharmacology: advances and applications 12 (2020): 171-176.
14. Reinhardt T., et al. "Chemical Proteomics Reveals Human Off-Targets of Fluoroquinolone Induced Mitochondrial Toxicity". Angewandte Chemie International Edition 64.18 (2025): e202421424.
15. Romanowska MJ., et al. "Fluoroquinolone-Induced Achilles Tendon Damage: Structural and Biochemical Insights into Collagen Type I Alterations". International Journal of Molecular Sciences 26.20 (2025): 10028.